Rebecca T Hahn1, Philippe Pibarot2, John Webb3, Josep Rodes-Cabau2, Howard C Herrmann4, Mathew Williams5, Raj Makkar6, Wilson Y Szeto4, Michael L Main7, Vinod H Thourani8, E Murat Tuzcu9, Samir Kapadia9, Jodi Akin10, Thomas McAndrew11, Ke Xu11, Martin B Leon5, Susheel K Kodali5. 1. Columbia University Medical Center/New York Presbyterian Hospital, New York, New York. Electronic address: rth2@columbia.edu. 2. Department of Medicine, Laval University, Quebec, Canada. 3. University of British Columbia and St. Paul's Hospital, Vancouver, Canada. 4. Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. 5. Columbia University Medical Center/New York Presbyterian Hospital, New York, New York. 6. Cedars-Sinai Medical Center, Los Angeles, California. 7. Saint Luke's Mid America Heart Institute, Kansas City, Missouri. 8. Emory University School of Medicine, Atlanta, Georgia. 9. Cleveland Clinic Foundation, Cleveland, Ohio. 10. Edwards Lifesciences, Irvine, California. 11. Cardiovascular Research Foundation, New York, New York.
Abstract
OBJECTIVES: This study sought to characterize the patients receiving post-implantation balloon dilation (PD) following transcatheter aortic valve replacement (TAVR) and evaluate procedural outcomes in the PARTNER (Placement of Aortic Transcatheter Valve) I trial. BACKGROUND: Following TAVR, PD has been used to treat paravalvular regurgitation. METHODS: The PARTNER I trial cohort A (n = 304) and cohort B (n = 194) patients randomized to TAVR and the nonrandomized continued access TAVR (n = 1,637) patients were included in the analysis. PD was performed at the discretion of the operator. Clinical events and echocardiographic variables were collected prospectively out to 1 year. RESULTS: The overall incidence of PD was 12.4%. PD patients had significantly less prosthesis-patient mismatch (p < 0.001) and larger effective orifice areas (p < 0.001) throughout the follow-up period. There were significantly more subacute strokes (occurring <7 days: 4.9% vs. 2.6%; p = 0.04) in PD patients but no difference in late stroke, either at 7 to 30 days (0.0% vs. 0.8%; p = 0.16) or >30 days (1.9 vs. 1.7%; p = 0.75). Although there was no significant increase in early mortality with PD, at 1 year, there was a trend for higher all-cause mortality (p = 0.054) and a significant difference in death or stroke (p = 0.04). When the subgroup of patients with none/trace paravalvular regurgitation were evaluated, there was no significant association of PD with mortality (p = 0.61) and death or stroke (p = 0.96). Multivariable analysis failed to show a relationship between PD and mortality. CONCLUSIONS: PD is associated with reduced rates of moderate or severe prosthesis-patient mismatch with no evidence for short-term structural deterioration of the balloon-expandable transcatheter valve. Although PD is associated with a greater incidence of early stroke, there is no significant association between PD and stroke beyond 7 days. Multivariable analysis shows no significant association between PD and mortality.
OBJECTIVES: This study sought to characterize the patients receiving post-implantation balloon dilation (PD) following transcatheter aortic valve replacement (TAVR) and evaluate procedural outcomes in the PARTNER (Placement of Aortic Transcatheter Valve) I trial. BACKGROUND: Following TAVR, PD has been used to treat paravalvular regurgitation. METHODS: The PARTNER I trial cohort A (n = 304) and cohort B (n = 194) patients randomized to TAVR and the nonrandomized continued access TAVR (n = 1,637) patients were included in the analysis. PD was performed at the discretion of the operator. Clinical events and echocardiographic variables were collected prospectively out to 1 year. RESULTS: The overall incidence of PD was 12.4%. PDpatients had significantly less prosthesis-patient mismatch (p < 0.001) and larger effective orifice areas (p < 0.001) throughout the follow-up period. There were significantly more subacute strokes (occurring <7 days: 4.9% vs. 2.6%; p = 0.04) in PDpatients but no difference in late stroke, either at 7 to 30 days (0.0% vs. 0.8%; p = 0.16) or >30 days (1.9 vs. 1.7%; p = 0.75). Although there was no significant increase in early mortality with PD, at 1 year, there was a trend for higher all-cause mortality (p = 0.054) and a significant difference in death or stroke (p = 0.04). When the subgroup of patients with none/trace paravalvular regurgitation were evaluated, there was no significant association of PD with mortality (p = 0.61) and death or stroke (p = 0.96). Multivariable analysis failed to show a relationship between PD and mortality. CONCLUSIONS:PD is associated with reduced rates of moderate or severe prosthesis-patient mismatch with no evidence for short-term structural deterioration of the balloon-expandable transcatheter valve. Although PD is associated with a greater incidence of early stroke, there is no significant association between PD and stroke beyond 7 days. Multivariable analysis shows no significant association between PD and mortality.
Authors: Matteo Pagnesi; Luca Baldetti; Paolo Del Sole; Antonio Mangieri; Marco B Ancona; Damiano Regazzoli; Nicola Buzzatti; Francesco Giannini; Antonio Colombo; Azeem Latib Journal: Interv Cardiol Date: 2017-09
Authors: Susheel Kodali; Vinod H Thourani; Jonathon White; S Chris Malaisrie; Scott Lim; Kevin L Greason; Mathew Williams; Mayra Guerrero; Andrew C Eisenhauer; Samir Kapadia; Dean J Kereiakes; Howard C Herrmann; Vasilis Babaliaros; Wilson Y Szeto; Rebecca T Hahn; Philippe Pibarot; Neil J Weissman; Jonathon Leipsic; Philipp Blanke; Brian K Whisenant; Rakesh M Suri; Raj R Makkar; Girma M Ayele; Lars G Svensson; John G Webb; Michael J Mack; Craig R Smith; Martin B Leon Journal: Eur Heart J Date: 2016-03-31 Impact factor: 29.983
Authors: Pier Pasquale Leone; Fabio Fazzari; Francesco Cannata; Jorge Sanz-Sanchez; Antonio Mangieri; Lorenzo Monti; Ottavia Cozzi; Giulio Giuseppe Stefanini; Renato Bragato; Antonio Colombo; Bernhard Reimers; Damiano Regazzoli Journal: Front Cardiovasc Med Date: 2021-06-04
Authors: Kashish Goel; Vuyisile T Nkomo; Joshua P Slusser; Ryan Lennon; Robert D Brown; Kevin L Greason; David R Holmes Journal: Open Heart Date: 2018-10-07
Authors: Yosuke Miyazaki; Rodrigo Modolo; Mohammad Abdelghani; Hiroki Tateishi; Rafael Cavalcante; Carlos Collet; Taku Asano; Yuki Katagiri; Erhan Tenekecioglu; Rogério Sarmento-Leite; José A Mangione; Alexandre Abizaid; Osama I I Soliman; Yoshinobu Onuma; Patrick W Serruys; Pedro A Lemos; Fabio S de Brito Journal: Arq Bras Cardiol Date: 2018-08 Impact factor: 2.000